Rik Ossenkoppele
91 – 100 of 145
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
-
Mark
Differential trajectories of hypometabolism across cognitively-defined Alzheimer's disease subgroups
(
- Contribution to journal › Article
- 2020
-
Mark
Hippocampal [18F]flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships
(
- Contribution to journal › Article
-
Mark
Combination of plasma amyloid beta(1-42/1-40)and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
(
- Contribution to journal › Article
-
Mark
A clinical-radiological framework of the right temporal variant of frontotemporal dementia
(
- Contribution to journal › Article
-
Mark
Latent atrophy factors related to phenotypical variants of posterior cortical atrophy
(
- Contribution to journal › Article
-
Mark
Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias
(
- Contribution to journal › Scientific review
-
Mark
Identifying a task-invariant cognitive reserve network using task potency
(
- Contribution to journal › Article
-
Mark
Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
(
- Contribution to journal › Article